Toggle Main Menu Toggle Search

Open Access padlockePrints

MAO-B Inhibitors Do Not Block In Vivo Flortaucipir ([18F]-AV-1451) Binding

Lookup NU author(s): Professor David BrooksORCiD



This is the authors' accepted manuscript of an article that has been published in its final definitive form by Springer US, 2018.

For re-use rights please refer to the publisher's terms and conditions.


Purpose: Recent evidence suggests that the tau radiotracer [18F]THK-5351 displays high affinity for the monoamine oxidase type B (MAO-B) enzyme. Utilizing another tau-tracer, flortaucipir ([18F]AV-1451), we previously reported that non-demented Parkinson’s disease patients show off-target binding in subcortical structures, but no appreciable cortical uptake. However, 59 % of these patients were receiving MAO-B inhibitors at the time of their scan. Here, we retrospectively investigated if MAO-B inhibitors in clinical doses affect flortaucipir binding. Procedures: We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson’s disease patients who received MAO-B inhibitors with those who did not. Results: Sixteen of 27 Parkinson’s disease patients received MAO-B inhibitors at the time of scan. We found no significant flortaucipir uptake differences between the groups at voxel or regional levels. Conclusion: Use of MAO-B inhibitors at pharmaceutical levels did not significantly affect flortaucipir binding. Thus, MAO-B does not appear to be a significant binding target of flortaucipir.

Publication metadata

Author(s): Hansen AK, Brooks DJ, Borghammer P

Publication type: Article

Publication status: Published

Journal: Molecular Imaging and Biology

Year: 2018

Volume: 20

Issue: 3

Pages: 356-360

Print publication date: 01/06/2018

Online publication date: 10/11/2017

Acceptance date: 01/09/2017

Date deposited: 15/01/2018

ISSN (print): 1536-1632

ISSN (electronic): 1860-2002

Publisher: Springer US


DOI: 10.1007/s11307-017-1143-1


Altmetrics provided by Altmetric